FierceBiotech9h
Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
pharmaphorum8h
Syncona aims Slingshot at biotech's 'translational gap'
"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...
GEN21h
Treehill CEO Sees Positives for Biopharma in Trump’s Re-Election
That differs by molecule, by company, by stage ... For example, Merck [& Co.] has over 480 combination products with Keytruda ...
Galecto Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...
pharmaphorum21h
Celgene hopes device + drug can tackle aggressive brain tumours
The latter will test its Keytruda in combination with Agenus' cancer vaccine Prophage. Another competitor is Regeneron which is investigating its own PD-1 inhibitor, REGN2810, alongside two ...